Asst Prof Stephanie Saw Pei Li

Dr Stephanie Saw graduated top of her class in 2013 from NUS Yong Loo Lin School of Medicine with multi-ple academic awards. Following her internal medicine junior residency, she subsequently completed her senior residency in medical oncology in 2019 and joined the Thoracic Oncology group in NCCS thereafter. Her research interest is in improving risk stratification of EGFR-mutated lung cancer, for which she obtained her PhD in Duke-NUS University in 2025 under the NMRC Research Training Fellowship. An aspiring clinician scientist, she was awarded the NMRC Transition Award in 2024 and hopes to integrate translational research into clinical practice through multidisciplinary collaboration.

• 2025: PhD in Clinical & Translational Sciences at Duke-NUS Medical University 
• 2016: MRCP (UK) and MMed (Int. Med) 
• 2013: MBBS (Hons)

• Scientific Committee Track Member of WCLC 2026 
• Editorial Board member of Journal of Thoracic Oncology 
• Scientific Committee Track Member of ESMO Asia 2024 
• Scientific Committee Track Member of WCLC 2022 
• Education Committee of Asian Thoracic Oncology Research Group 
• Co-chair of NCCS Pharmacy Cost Review Workgroup 
• Committee member of LEAP (Lung Cancer Education and Advocacy for Patients)

• NMRC Transition Award 2024 
• NCCS Cancer Fund (Research) 2024 
• Conquer Cancer Merit Award for ASCO Breakthrough 2023 
• Merit Travel Grant for European Lung Cancer Conference 2023 
• COVID-19 Resilience Medal 2023 
• International Lung Cancer Foundation Young Investigator Grant 2022 
• International Association for the Study of Lung Cancer (IASLC) Academy Award 2022 
• National Cancer Centre Singapore (NCCS) Research Publication Award 2022 
• Singapore Health Quality Service Silver Award 2022 
• Outstanding Resident Award 2018 
• In-Training-Examination Gold Medal 2014 
• Dean’s List; Lee Kuan Yew Gold Medal; Infectious Disease Prize; Nestle Medal 2013 
• Dean’s List 2012 
• Dean’s List; Medical Alumni Association Silver Medal 2011 
• Dean’s List; Medical Class of 1975 Medal 2010 
• Dean’s List; Thambipillai Medal 2009

• Saw, S.P.L., and Li, M.S.C. (2025). Distant Cousins From the Same Family—Understanding Uncom-mon EGFR Mutations. Journal of Thoracic Oncology 20, 415–418. https://doi.org/10.1016/j.jtho.2025.01.007. 
• Saw, S.P.L., Takano, A., Zhou, S., Hlaing, N.O., James, A., Joseph, C., Lai, G.G.Y., Lim, D.W.T., Kanesvaran, R., Ang, M.-K., et al. (2025). EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer. Lung Cancer 202, 108463. https://doi.org/10.1016/j.lungcan.2025.108463. 
• Mountzios, G., Saw, S.P.L., Hendriks, L., Menis, J., Cascone, T., Arrieta, O., Naidoo, J., Koutoukoglou, P., Cani, M., Lefevre, A., et al. (2025). Antibody-drug conjugates in NSCLC with ac-tionable genomic alterations: Optimizing smart delivery of chemotherapy to the target. Cancer Treat-ment Reviews 134, 102902. https://doi.org/10.1016/j.ctrv.2025.102902. 
• Remon, J., & Saw, S. P. L. (n.d.). Teliso-V and osimertinib: The METamorphosis of EGFR-mutant lung cancer? Annals of Oncology. https://doi.org/10.1016/j.annonc.2025.01.008 
• Saw, S. P. L., Zhong, W.-Z., Fu, R., Li, M. S. C., Goto, Y., Fox, S. B., Yatabe, Y., Ong, B.-H., Ng, C. S. H., Lee, D. D. W., Cam Phuong, P., Park, I. K., Yang, J. C. H., Tsuboi, M., Tho, L. M., John, T., Hsu, H.-H., Tan, D. S. W., Mok, T. S. K., … Singh, N. (2025). Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer. Lung Cancer, 200. https://doi.org/10.1016/j.lungcan.2024.108076 
• Li, M. S. C., Saw, S. P. L., & Addeo, A. (2024). Anti-CTLA-4 in non-small-cell lung cancer: Insights from the NIPPON study. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(24)00218-2. 
• Saw, S. P. L., Low, Y. F., Lai, G. G. Y., Chan, L. L., Wong, W. K. Y., Tsui, G., Chen, O. H., Seet, A. O. L., Tan, W. C., Tan, A. C., Chan, J. W. K., Teh, Y. L., Tan, W.-L., Ng, Q. S., Ang, M.-K., Kanesvaran, R., Lim, D. W. T., Tan, D. S. W., Mok, T. S. K., & Li, M. S. C. (2024). Real-world out-comes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimer-tinib in advanced EGFR-mutated NSCLC. Lung Cancer, 193. https://doi.org/10.1016/j.lungcan.2024.107856 
• Saw, S. P. L., Le, X., Hendriks, L. E. L., & Remon, J. (2024). New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors. American Society of Clinical Oncology Educational Book, 44(3), e432516. https://doi.org/10.1200/EDBK_432516 
• Huang, C.-Y., Jiang, N., Shen, M., Lai, G. G., Tan, A. C., Jain, A., Saw, S. P., Ang, M. K., Ng, Q. S., Lim, D. W., Kanesvaran, R., Tan, E. H., Tan, W. L., Ong, B.-H., Chua, K. L., Anantham, D., Takano, A. M., Lim, K. H., Tam, W. L., … Rozen, S. G. (2024). Oncogene-driven non-small cell lung cancers in patients with a history of smoking lack smoking-induced mutations. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-23-2551 
• Tan, A. C., Lai, G. G. Y., Saw, S. P. L., Chua, K. L. M., Takano, A., Ong, B.-H., Koh, T. P. T., Jain, A., Tan, W. L., Ng, Q. S., Kanesvaran, R., Rajasekaran, T., Kalashnikova, E., Renner, D., Sudhaman, S., Malhotra, M., Sethi, H., Liu, M. C., Aleshin, A., … Tan, D. S. W. (2024). Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Cancer, 130(10), 1758–1765. https://doi.org/10.1002/cncr.35263 
• Saw, S. P. L., San Tan, G., Tan, W. C., Tan, A. C., Lai, G. G. Y., Lim, D. W. T., Kanesvaran, R., Tan, W. L., Tan, S. H., Lim, K. H., Skanderup, A. J., & Tan, D. S. W. (2023). “Brief Report: ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations and CEA levels as a surrogate measure”. JTO Clinical and Research Reports, 100599. https://doi.org/10.1016/j.jtocrr.2023.100599 
• Remon, J., Saw, S. P. L., Cortiula, F., Singh, P. K., Menis, J., Mountzios, G., & Hendriks, L. E. L. (2023). Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2023.09.1451 
• Saw, S. P. L., & Lim, D. W.-T. (2023). Diverse Resistant Mechanisms Identified Using Serial Next-Generation Sequencing in a Patient With ALK-Rearranged Metastatic Lung Adenocarcinoma: A Case Report. JTO Clinical and Research Reports, 4(6), 100512. https://doi.org/10.1016/j.jtocrr.2023.100512 
• Saw, S. P. L., Ng, W. P., Zhou, S., Lai, G. G. Y., Tan, A. C., Ang, M.-K., Lim, W.-T., Kanesvaran, R., Ng, Q. S., Jain, A., Tan, W. L., Rajasekaran, T., Chan, J. W. K., Teh, Y. L., Pang, M., Yeo, J.-C., Takano, A., Ong, B.-H., Tan, E.-H., … Tan, D. S. W. (2023). PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. European Journal of Can-cer, 178, 139–149. https://doi.org/10.1016/j.ejca.2022.10.012 
• Saw, S. P. L., Chua, K. L. M., Ong, B. H., Lim, D. W. T., Lai, G. G. Y., Tan, D. S. W., & Ang, M. K. (2022). Multidisciplinary lung cancer clinic: An emerging model of care. Ann Acad Med Singap, 51(12), 793–795. PubMed. https://doi.org/10.47102/annals-acadmedsg.2022295